Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof
US12059412B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2019 |
| Grant date | Aug 13, 2024 |
| Priority date | — |
| Expiry date | Aug 29, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.